While Kittrell didn’t take the money, other’s have—and they’re part of a growing network of ambassadors for telehealth companies paid to promote compounded weight-loss medications.

Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out drugs are emerging.